XORTX Therapeutics Expands Pipeline with Late-Stage Gout Program

An announcement from XORTX Therapeutics Inc ( (TSE:XRTX) ) is now available.

XORTX Therapeutics Inc. announced the addition of a late-stage program aimed at treating gout in patients intolerant to allopurinol, a common xanthine oxidase inhibitor. The new program, XRx-026, will involve discussions with the FDA for a New Drug Application and potential orphan drug designation. The initiative highlights XORTX’s commitment to addressing significant unmet medical needs in the gout treatment market, particularly given the decline in use of alternative treatment Febuxostat due to safety concerns.

More about XORTX Therapeutics Inc

XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease. The company is actively involved in creating solutions for unmet medical needs, particularly in the realm of kidney disorders, and is listed on NASDAQ, TSXV, and Frankfurt Borse.

YTD Price Performance: 9.04%

Average Trading Volume: 5,006

Technical Sentiment Consensus Rating: Strong Buy

Current Market Cap: C$6.3M

Find detailed analytics on XRTX stock on TipRanks’ Stock Analysis page.